Essential Partners’s Inhibrx INBX Stock Holding History

Essential Partners’s Portfolio INBX Stock Details INBX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$190	Hold	2	–	–	﹤0.01%	2648
2026 Q1	$134	Hold	2	–	–	﹤0.01%	2675
2025 Q4	$158	Hold	2	–	–	﹤0.01%	2474
2025 Q3	$67	Hold	2	–	–	﹤0.01%	2539
2025 Q2	$29	Buy	+2	New	+$26	﹤0.01%	2197

Other funds holding INBX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $104B AUM 28.3% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Essential Partners's INBX Position: Q2 2026 in Review

Essential Partners held its Inhibrx (INBX) position steady in Q2 2026 at 2 shares worth $190. The position accounts for ﹤0.01% of the portfolio, ranked #2648.

Essential Partners first reported a position in INBX in Q2 2025 and has held it in 5 quarters since. 163 funds tracked by Wall St. Rank hold INBX as of Q2 2026.

Essential Partners held 2 shares of Inhibrx worth $190 as of Q2 2026.
Essential Partners left its Inhibrx share count unchanged in Q2 2026.
Inhibrx made up ﹤0.01% of Essential Partners's portfolio in Q2 2026, its #2648 holding.
Essential Partners first reported a position in Inhibrx in Q2 2025 and has held it in 5 quarters since.
163 funds tracked by Wall St. Rank held Inhibrx as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.